NO882218D0 - PROCEDURE FOR THE PREPARATION OF PHOSPHORUS HMG-COA REDUCTASE INHIBITORS. - Google Patents

PROCEDURE FOR THE PREPARATION OF PHOSPHORUS HMG-COA REDUCTASE INHIBITORS.

Info

Publication number
NO882218D0
NO882218D0 NO882218A NO882218A NO882218D0 NO 882218 D0 NO882218 D0 NO 882218D0 NO 882218 A NO882218 A NO 882218A NO 882218 A NO882218 A NO 882218A NO 882218 D0 NO882218 D0 NO 882218D0
Authority
NO
Norway
Prior art keywords
hmg
phosphorus
procedure
preparation
coa reductase
Prior art date
Application number
NO882218A
Other languages
Norwegian (no)
Other versions
NO882218L (en
Inventor
Donald Steven Karanewsky
Scott Adams Biller
Eric Michael Gordon
Original Assignee
Squibb & Sons Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Squibb & Sons Inc filed Critical Squibb & Sons Inc
Publication of NO882218D0 publication Critical patent/NO882218D0/en
Publication of NO882218L publication Critical patent/NO882218L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/32—Esters thereof
    • C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids R2P(=O)(OH); Thiophosphinic acids, i.e. R2P(=X)(XH) (X = S, Se)
    • C07F9/36—Amides thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C07F9/44—Amides thereof
    • C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
NO882218A 1987-05-22 1988-05-20 PROCEDURE FOR THE PREPARATION OF PHOSPHORUS HMG-COA REDUCTASE INHIBITORS. NO882218L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5328187A 1987-05-22 1987-05-22
US10968087A 1987-10-19 1987-10-19

Publications (2)

Publication Number Publication Date
NO882218D0 true NO882218D0 (en) 1988-05-20
NO882218L NO882218L (en) 1988-11-23

Family

ID=26731667

Family Applications (1)

Application Number Title Priority Date Filing Date
NO882218A NO882218L (en) 1987-05-22 1988-05-20 PROCEDURE FOR THE PREPARATION OF PHOSPHORUS HMG-COA REDUCTASE INHIBITORS.

Country Status (24)

Country Link
JP (1) JP2680347B2 (en)
KR (1) KR880013958A (en)
CN (1) CN88103091A (en)
AU (1) AU610591B2 (en)
BE (1) BE1004193A3 (en)
CH (1) CH676984A5 (en)
DE (1) DE3817375C2 (en)
DK (1) DK277488A (en)
ES (1) ES2009918A6 (en)
FI (1) FI89493C (en)
FR (1) FR2615508B1 (en)
GB (1) GB2205837B (en)
GR (1) GR1000959B (en)
HU (1) HU205125B (en)
IE (2) IE63760B1 (en)
IL (1) IL86464A (en)
IT (1) IT1217685B (en)
NL (1) NL8801330A (en)
NO (1) NO882218L (en)
NZ (1) NZ224733A (en)
PH (1) PH25350A (en)
PL (1) PL154877B1 (en)
PT (1) PT87539B (en)
SE (1) SE503210C2 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK277388A (en) * 1987-05-22 1988-11-23 Squibb & Sons Inc PHOSPHORUS HMG-COA REDUCTASE INHIBITORS, INTERMEDIATES AND PROCEDURE
CA2007643A1 (en) * 1989-02-01 1990-08-01 Donald S. Karanewsky Combination of an hmg coa reductase inhibitor and a squalene synthetase inhibitor and method for lowering serum cholesterol using such combination
CA2042526A1 (en) * 1990-06-11 1991-12-12 Adeoye Y. Olukotun Method for preventing a second heart attack employing an hmg coa reductase inhibitor
US5202327A (en) * 1991-07-10 1993-04-13 E. R. Squibb & Sons, Inc. Phosphorus-containing hmg-coa reductase inhibitors
GB9126144D0 (en) * 1991-12-10 1992-02-12 British Bio Technology Compounds
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
SK3202001A3 (en) 1998-09-17 2002-04-04 Bristol Myers Squibb Co Drug and a pharmaceutical composition for treating diabetes, insulin resistance, obesity, hyperglycemia, hyperinsulinemia or increased level
HUP0600232A2 (en) 2001-04-11 2006-08-28 Bristol Myers Squibb Co Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
GEP20063908B (en) 2001-10-18 2006-08-25 Bristol Myers Squibb Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
EP1553937B1 (en) 2002-10-23 2010-06-02 Bristol-Myers Squibb Company Glycinenitrile-based inhibitors of dipeptidyl peptidase iv
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
DK1725234T4 (en) 2004-03-05 2016-05-09 Univ Pennsylvania METHODS OF TREATING DISEASES OR DISEASES CONNECTED WITH HYPERLIPIDEMIA AND HYPERCOLESTEROLYMIA WITH MINIMIZATION OF SIDE EFFECTS
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
AR051446A1 (en) 2004-09-23 2007-01-17 Bristol Myers Squibb Co C-ARYL GLUCOSIDS AS SELECTIVE INHIBITORS OF GLUCOSE CONVEYORS (SGLT2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7361766B2 (en) 2005-01-12 2008-04-22 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7314882B2 (en) 2005-01-12 2008-01-01 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076597A1 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en) 2005-01-18 2006-07-20 Chongqing Sun Bicyclic heterocycles as cannabinoid receptor modulators
WO2006113261A2 (en) 2005-04-14 2006-10-26 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
US8618115B2 (en) 2005-10-26 2013-12-31 Bristol-Myers Squibb Company Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
WO2007053819A2 (en) 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US20100022457A1 (en) 2006-05-26 2010-01-28 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
AR065809A1 (en) 2007-03-22 2009-07-01 Bristol Myers Squibb Co PHARMACEUTICAL FORMULATIONS CONTAINING AN SGLT2 INHIBITOR
PE20090696A1 (en) 2007-04-20 2009-06-20 Bristol Myers Squibb Co CRYSTALLINE FORMS OF SAXAGLIPTIN AND PROCESSES FOR PREPARING THEM
WO2009023059A2 (en) 2007-06-01 2009-02-19 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EP2173717B9 (en) 2007-07-27 2013-06-26 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
NZ583495A (en) 2007-09-20 2011-11-25 Irm Llc Compounds and compositions as modulators of gpr119 activity
PE20091928A1 (en) 2008-05-29 2009-12-31 Bristol Myers Squibb Co HAVE HYDROXYSUSTITUTED PYRIMIDINES AS NON-BASIC MELANIN-CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
CA2756786A1 (en) 2009-03-27 2010-09-30 Bristol-Myers Squibb Company Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
BR112012008004A2 (en) 2009-10-09 2016-03-29 Irm Llc compounds and compositions as modulators of gpr119 activity
MX2012005425A (en) 2009-11-13 2012-06-14 Astrazeneca Uk Ltd Reduced mass metformin formulations.
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
WO2011060256A2 (en) 2009-11-13 2011-05-19 Bristol-Myers Squibb Company Bilayer tablet formulations
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
MX342120B (en) 2010-07-09 2016-09-14 William Owen Wilkison Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin.
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (en) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 Compositions comprising and methods of using inhibitors of sodium-glucose cotransporters 1 and 2
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
ES2869286T3 (en) 2012-11-20 2021-10-25 Lexicon Pharmaceuticals Inc Sodium-glucose cotransporter 1 inhibitors
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
CN104610262B (en) * 2013-11-01 2017-06-06 上海医药工业研究院 Biphenyl compound, intermediate, preparation method, pharmaceutical composition and its application
KR20170138570A (en) 2015-04-30 2017-12-15 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Anti-aP2 antibodies and antigen binding substances for the treatment of metabolic disorders
CR20210029A (en) 2018-07-19 2021-02-26 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
SG11202102498UA (en) 2018-09-26 2021-04-29 Lexicon Pharmaceuticals Inc Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828650B (en) * 1981-12-01 1983-09-28 Hunt Chem Corp Philip A Herbicidal compositions and method using phosphonalkanoic acids, esters and salts thereof
FR2596393B1 (en) * 1986-04-01 1988-06-03 Sanofi Sa HYDROXY-3 DIHYDROXYOXOPHOSPHORIO-4 BUTANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS, THEIR USE AS MEDICAMENTS AND THE COMPOSITIONS CONTAINING THEM
DK277388A (en) * 1987-05-22 1988-11-23 Squibb & Sons Inc PHOSPHORUS HMG-COA REDUCTASE INHIBITORS, INTERMEDIATES AND PROCEDURE

Also Published As

Publication number Publication date
DE3817375A1 (en) 1988-12-08
PH25350A (en) 1991-05-13
NL8801330A (en) 1988-12-16
ES2009918A6 (en) 1989-10-16
GR1000959B (en) 1993-03-16
NZ224733A (en) 1990-12-21
FR2615508A1 (en) 1988-11-25
PT87539B (en) 1992-09-30
SE8801903D0 (en) 1988-05-20
FR2615508B1 (en) 1994-11-25
GR880100331A (en) 1989-02-23
IE881543L (en) 1988-11-22
SE503210C2 (en) 1996-04-22
GB2205837B (en) 1991-11-20
IL86464A (en) 1993-06-10
PT87539A (en) 1989-05-31
FI89493C (en) 1993-10-11
HU205125B (en) 1992-03-30
IL86464A0 (en) 1988-11-15
IE63760B1 (en) 1995-06-14
HUT49358A (en) 1989-09-28
GB8811929D0 (en) 1988-06-22
SE8801903L (en) 1988-11-23
FI89493B (en) 1993-06-30
NO882218L (en) 1988-11-23
AU1650888A (en) 1988-11-24
DK277488D0 (en) 1988-05-20
IE930324L (en) 1988-11-22
FI882384A (en) 1988-11-23
JPS6456689A (en) 1989-03-03
AU610591B2 (en) 1991-05-23
KR880013958A (en) 1988-12-22
BE1004193A3 (en) 1992-10-13
IT8820682A0 (en) 1988-05-20
DK277488A (en) 1988-11-23
JP2680347B2 (en) 1997-11-19
CH676984A5 (en) 1991-03-28
PL154877B1 (en) 1991-09-30
FI882384A0 (en) 1988-05-20
DE3817375C2 (en) 1997-04-30
CN88103091A (en) 1988-12-21
IT1217685B (en) 1990-03-30
GB2205837A (en) 1988-12-21
PL272597A1 (en) 1989-03-06

Similar Documents

Publication Publication Date Title
NO882218D0 (en) PROCEDURE FOR THE PREPARATION OF PHOSPHORUS HMG-COA REDUCTASE INHIBITORS.
NO860371L (en) PROCEDURE FOR THE PREPARATION OF PEPTIDASE INHIBITORS.
NO885605L (en) PROCEDURE FOR THE MANUFACTURE OF LUBRICANE OIL.
NO885106D0 (en) PROCEDURE FOR THE PREPARATION OF CYTIDIN DERIVATIVES.
NO882219D0 (en) PROCEDURE FOR THE PREPARATION OF PHOSPHORUS HMG-COA REDUCTASE INHIBITORS.
NO170071C (en) PROCEDURE FOR THE PREPARATION OF CHLORODIOXIDE.
NO880262L (en) PROCEDURE FOR THE PREPARATION OF B AVERMECTINES.
NO880068L (en) PROCEDURE FOR THE PREPARATION OF HETEROARYL-3-OXO-PROPANNITRIL DERIVATIVES.
NO872356D0 (en) PROCEDURE FOR THE PREPARATION OF MONOCALIUM PHOSPHATE.
NO884665D0 (en) PROCEDURE FOR THE PREPARATION OF 9-OH-ALCOXYGUANINE.
PT88364A (en) PROCESS FOR PREPARING NOVEL HMG-COA REDUCTASE INHIBITORS
NO883145L (en) PROCEDURE FOR THE PREPARATION OF TIENOIMIDAZOLE DERIVATIVES.
NO885002D0 (en) PROCEDURE FOR THE PREPARATION OF SIALOCYL GLYCEROLIPIDES.
NO882730L (en) PROCEDURE FOR THE PREPARATION OF AMINOCYCLOPENTYLETERS.
NO901422L (en) PROCEDURE FOR THE PREPARATION OF ALFA-GLUCOSIDASE INHIBITORS.
NO881055D0 (en) PROCEDURE FOR THE PREPARATION OF OXO-ISOINDOLINYL DERIVATIVES.
NO880106D0 (en) PROCEDURE FOR THE PREPARATION OF THE LALKNITROGEN.
NO883610D0 (en) PROCEDURE FOR THE PREPARATION OF SUBSTITUTED TIENOIMIDAZOLE DERIVATIVES.
NO880834D0 (en) PROCEDURE FOR THE PREPARATION OF HETEROCYCLYL-2-PROPYN-1-AMINES.
NO872355D0 (en) PROCEDURE FOR THE PREPARATION OF MONOCALIUM PHOSPHATE.
NO892761D0 (en) PROCEDURE FOR MANUFACTURING INHIBITORS FOR 3-KETO-HMG-COA REDUCTASE.
NO913089L (en) PROCEDURE FOR THE PREPARATION OF TETRAZOLIC COMPOUNDS.
NO890375L (en) PROCEDURE FOR THE PREPARATION OF HEXANITROSTILBEN.
NO880844L (en) PROCEDURE FOR THE PREPARATION OF CYTOTOXINES.
NO871521L (en) PROCEDURE FOR THE PREPARATION OF BENZOCSA - BENZOTIA DIAZOLD DERIVATIVES.